Fluconazole and Enhanced Effect of Rifabutin Prophylaxis

Publisher Website
Google Scholar
Abstract
The results of two double-blind, randomized, placebo-controlled trials published in the Journal (Sept. 16 issue)1 have shown that prophylactic treatment with rifabutin (300 mg per day) significantly reduces the incidence of Mycobacterium avium complex bacteremia. A Special Report in the same issue2 further recommends rifabutin prophylaxis in adults and adolescents with human immunodeficiency virus infection and CD4+ counts of 100 cells or less per cubic millimeter and suggests that effective primary prophylaxis could improve the patients' quality of life and survival.